SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 11 of 21
Word Count: 1432
Character Count: 9043

Document Content:

products or (z) a termination or suspension of marketing, testing or distribution of any of the Company’s products or services. Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith, based on the information available to the Company as of the Effective Date. Covenants of the Company. The Company covenants and agrees as follows: Amendments to Registration Statement. The Company shall deliver to the Representative, prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date and not file any such amendment or supplement to which the Representative shall reasonably object in writing. Federal Securities Laws.

Compliance. The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations,
and will, during the period required to permit the completion of the distribution of the Public Shares, the Representative’s Warrants
and the Representative Warrant Shares as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, notify the Representative promptly, and confirm the notice in writing, (i) when any post-effective amendment to the
Registration Statement shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii) of the receipt
of any comments from the Commission; (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment
or supplement to the Prospectus or for additional information; (iv) of the issuance by the Commission of any stop order suspending the
effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary
Prospectus or the Prospectus, or of the suspension of the qualification of the Public Shares, the Representative’s Warrants or
the Representative Warrant Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for
any of such purposes or of any examination pursuant to Section 8(d) or 8(e) of the Securities Act concerning the Registration Statement;
and (v) if the Company becomes the subject of a proceeding under Section 8A of the Securities Act in connection with the Offering of
the Public Shares, the Representative’s Warrants or the Representative Warrant Shares. The Company shall effect all filings required
under Rule 424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance
on Rule 424(b)(8)), and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted
for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such
prospectus. The Company shall use its commercially reasonable efforts to prevent the issuance of any stop order, prevention or suspension
and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment.

Continued Compliance. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the
Exchange Act Regulations so as to permit the completion of the distribution of the Public Shares, the Representative’s Warrants
and the Representative Warrant Shares as contemplated in this Agreement and in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. If at any time when a prospectus relating to the Public Shares, the Representative’s Warrants and/or the Representative
Warrant Shares is (or, but for the exception afforded by Rule 172 of the Securities Act Regulations (“Rule 172”),
would be) required by the Securities Act to be delivered in connection with sales of such securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i) amend the
Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii) amend or supplement the
Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in light of the circumstances existing at the time it is delivered to a purchaser or (iii) amend the Registration Statement
or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the Securities Act or the Securities Act Regulations, the Company will promptly (A) give the Representative notice of such event;
(B) prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement,
the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed
filing or use, furnish the Representative with copies of any such amendment or supplement and (C) file with the Commission any such amendment
or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative or counsel
for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment or
supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant to
the Exchange Act or the Exchange Act Regulations within 48 hours prior to the Applicable Time. The Company shall give the Representative
notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and any Option Closing Date
and will furnish the Representative with copies of the related document(s) a reasonable amount of time prior to such proposed filing,
as the case may be, and will not file or use any such document to which the Representative or counsel for the Underwriters shall reasonably
object.

Exchange Act Registration. For a period of two (2) years after the date of this Agreement, the Company shall use its commercially
reasonable efforts to maintain the registration of the Common Stock under the Exchange Act, unless the Company is taken private in a
bona fide acquisition transaction. During such two (2) year period, the Company shall not deregister the Common Stock under the Exchange
Act without the prior written consent of the Representative, which consent shall not be unreasonably withheld.

Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall
not make any offer relating to the Public Shares, the Representative’s Warrants or the Representative Warrant Shares that would
constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion
thereof, required to be filed by the Company with the Commission or retained by the Company under Rule 433; provided that the Representative
shall be deemed to have consented to each Issuer General Use Free Writing Prospectus hereto and any “road show that is a written
communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Representative. The Company represents that
it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed consented to, by the Underwriters
as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable
requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping.
If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of
which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or
included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances existing at that subsequent time, not misleading, the Company will promptly
notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or
correct such conflict, untrue statement or omission.